(Utkast) Kommisjonens gjennomføringsbeslutning (EU) .../... om oppheving av gjennomføringsbeslutning (EU) 2022/1487 og (EU) 2025/434 om utsettelse av utløpsdatoen for godkjenningen av etofenproks til bruk i biocidprodukter av henholdsvis type 8 og 18, i samsvar med europaparlaments- og rådsforordning (EU) nr. 528/2012
Biocider: oppheving av forlengelse av godkjenning av etofenproks til bruk i biocidprodukter i produkttype 8 og 18
(Draft) Commission Implementing Decision (EU) .../... repealing Implementing Decisions (EU) 2022/1487 and (EU) 2025/434 postponing the expiry dates of the approval of etofenprox for use in biocidal products of product-types 8 and 18, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Utkast til kommisjonsbeslutning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 29.1.2026
Bakgrunn
(fra kommisjonsbeslutningen)
(1) Etofenprox was included in Annex I to Directive 98/8/EC of the European Parliament and of the Council as an active substance for use in biocidal products of product-type 8. Pursuant to Article 86 of Regulation (EU) No 528/2012, it was therefore considered approved under that Regulation subject to the requirements set out in Annex I to Directive 98/8/EC.
(2) The approval of etofenprox for use in biocidal products of product-type 8 was to expire on 31 January 2020. On 27 July 2018, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of that approval.
(3) By Commission Implementing Decision (EU) 2019/994 , the Commission postponed the expiry date of the approval of etofenprox for use in biocidal products of product-type 8 to 31 October 2022, in order to allow sufficient time for the examination of the application for the renewal of that approval. By Commission Implementing Decision (EU) 2022/1487 , the Commission further postponed the expiry date of that approval to 31 October 2026, due to delays linked with studies needed to assess the criteria for the determination of endocrine-disrupting properties of etofenprox.
(4) Etofenprox was also approved as an active substance for use in biocidal products of product-type 18 by Commission Implementing Regulation (EU) No 1036/2013 , subject to the specifications and conditions set out in the Annex to that Implementing Regulation.
(5) The approval of etofenprox for use in biocidal products of product-type 18 was to expire on 30 June 2025. On 25 October 2023, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of that approval.
(6) By Commission Implementing Decision (EU) 2025/434 , the Commission postponed the expiry date of the approval of etofenprox for use in biocidal products of product-type 18 to 31 December 2027, to allow sufficient time for the examination of the application for the renewal of the approval of etofenprox for use in biocidal products of product-type 18.
(7) However, on 12 June 2025, the applicant who submitted the applications for the renewal of the approval of etofenprox for use in biocidal products of product-types 8 and 18 informed the Commission that it had withdrawn both applications.
(8) Consequently, as it has not been established that etofenprox still meets the conditions laid down in Article 4(1) of Regulation (EU) No 528/2012, pursuant to Commission Implementing Decision (EU) C(2025) 7500 [Publications office please add here the number of this Decision once it is associated, along the whole Decision] the approval of etofenprox for use in biocidal products of product-types 8 and 18 was not renewed. Therefore, it is appropriate to repeal Implementing Decisions (EU) 2022/1487 and (EU) 2025/434 postponing the expiry dates of the approval of etofenprox for use in biocidal products of product-types 8 and 18, respectively,